13 Sep 2018 GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors
12 Sep 2018 FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
12 Sep 2018 Innate PHARMA announces enrollment of first patient in the phase i study of IPH5401 in combination with durvalumab (IMFINZI®) in solid tumors
12 Sep 2018 BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study
11 Sep 2018 First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody as First-line Treatment for Patients with Non-Squamous Non-Small Cell Lung Cancer
10 Sep 2018 Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
10 Sep 2018 Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis
10 Sep 2018 Innovent's Anti-CD47 Antibody IBI188 Receives IND Approval in China
10 Sep 2018 Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars
10 Sep 2018 European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
10 Sep 2018 GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
08 Sep 2018 Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
07 Sep 2018 Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
07 Sep 2018 FDA Approves Grifols New GamaSTAN® (immune globulin [human]) to Treat Patients Exposed to Hepatitis A and Measles
06 Sep 2018 MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA
06 Sep 2018 Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
06 Sep 2018 argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
05 Sep 2018 Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
05 Sep 2018 Aduro Biotech Presents Preclinical Data for BION-1301, a First-in-Class Antibody Targeting Human APRIL, at the 2018 European Congress of Immunology
04 Sep 2018 Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
04 Sep 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer
03 Sep 2018 Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
02 Sep 2018 Kodiak Sciences Announces Completion of Enrollment in the Company's Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
31 Aug 2018 Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Front Line Multiple Myeloma
31 Aug 2018 European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up